Skip to main content

Advertisement

SpringerLink
Log in

Use of tumor lines with selectable markers in assessing the effect on experimental metastases of combination chemotherapy with alkylating agents

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

High-dose chemotherapy with a 3-day regimen of cyclophosphamide, cisplatin, and carmustine was used to treat mice bearing experimental lung metastases of mammary tumor cell lines with selectable markers (lines 66cl4 and 4TO7). Cloning of lung cells at various times after treatment revealed a rapid 3 to 4 log loss of clonogenic tumor cells, down to undetectable levels. However, after several weeks, clonogenic tumor cells reappeared in the lungs; few cures were obtained even when mice had a relatively low tumor burden when treated with chemotherapy. Splenocyte numbers and response to Concanavalin A indicated a transient immunosuppression. In one experiment, mice were treated with a second round of chemotherapy 3 weeks after the first. The number of clonogenic cells per lung again dropped, but regrowth of cells was rapid, and no cures were obtained. Inoculation of tumor-bearing mice s.c. after chemotherapy with lethally irradiated cells of the highly immunogenic tumor cell line 4TO7-IL-2 had little effect on the rate of reappearance of line 4TO7 in lungs, but subsequent growth of tumor cells in lungs was slowed. This model system can be used to test the efficacy of additional immunotherapy and chemotherapy regimens on minimal residual metastatic disease after high-dose chemotherapy, when remaining metastatic cells are apparently dormant. © Rapid Science Ltd.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Peters WP, Shpall EJ, Jones RB, et al. 1988, High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol, 6, 1368-76.

    PubMed  CAS  Google Scholar 

  2. Peters WP, Ross M, Vredenburgh JJ, et al. 1993, High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high risk primary breast cancer. J Clin Oncol, 11, 1132-43.

    PubMed  CAS  Google Scholar 

  3. Talmadge JE, Jackson JD, Kelsey L, Borgeson CD, Faltynek C and Perry GA, 1993, T-cell reconstitution by molecular, phenotypic, and functional analysis in the thymus, bone marrow, spleen, and blood following split-dose polychemotherapy and therapeutic activity for metastatic breast cancer in mice. J Immunother, 14, 258-68.

    Article  CAS  Google Scholar 

  4. Talmadge JE, Jackson JD, Borgeson CD and Perry GA, 1994, Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus bone marrow, spleen and blood of mice following split-dose polychemotherapy. Cancer Immunol Immunother, 39, 59-67.

    Article  PubMed  CAS  Google Scholar 

  5. Heppner GH, Dexter DR, DeNucci T, Miller FR and Calabresi P, 1978, Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mouse mammary tumor. Cancer Res, 38, 3758-63.

    PubMed  CAS  Google Scholar 

  6. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R and Heppner GH, 1978, Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res, 38, 3174-81.

    PubMed  CAS  Google Scholar 

  7. Blazer BA, Laing CA, Miller FR and Heppner GH, 1980, Activity of lymphoid cells separated from mammary tumors in blastogenesis and Winn assays. J Natl Cancer Inst, 65, 405-10.

    Google Scholar 

  8. Miller BE, Miller FR, Wilburn D and Heppner GH, 1987, Analysis of tumour cell composition in tumours composed of paired mixtures of mammary tumour cell lines. Br J Cancer, 56, 561-9.

    PubMed  CAS  Google Scholar 

  9. Aslakson CJ and Miller FR, 1992, Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res, 52, 1398-405.

    Google Scholar 

  10. Miller BE, Roi LD, Howard LM and Miller FR, 1983, Quantitative selectivity of contact-mediated intercellular communication in a metastatic mouse mammary tumor line. Cancer Res, 43, 4102-7.

    PubMed  CAS  Google Scholar 

  11. Miller BE, McInerney D, Jackson D and Miller FR, 1986, Metabolic cooperation between mouse mammary tumor subpopulations in three-dimensional collagen gel cultures. Cancer Res, 46, 89-93.

    PubMed  CAS  Google Scholar 

  12. Miller BE, Miller FR and Heppner GH, 1981, Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate. Cancer Res, 41, 4378-81.

    PubMed  CAS  Google Scholar 

  13. Miller BE, Miller FR and Heppner GH, 1985, Factors affecting growth and drug sensitivity of mouse mammary tumor lines in collagen gel culture. Cancer Res, 45, 4200-5.

    PubMed  CAS  Google Scholar 

  14. Miller BE, Machemer T, Lehotan M and Heppner GH, 1991, Tumor subpopulation interactions affecting melphalan sensitivity in palpable mouse mammary tumors. Cancer Res, 51, 4378-87.

    PubMed  CAS  Google Scholar 

  15. Miller FR, Miller BE and Heppner GH, 1983, Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis, 3, 22-31.

    PubMed  CAS  Google Scholar 

  16. Miller FR and Heppner GH, 1979, Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. J Natl Cancer Inst, 63, 1457-63.

    PubMed  CAS  Google Scholar 

  17. Miller BE, Miller FR, Wilburn D and Heppner GH, 1988, Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. Cancer Res, 48, 5747-53.

    PubMed  CAS  Google Scholar 

  18. Miller BE, Miller FR and Heppner GH, 1989, Therapeutic perturbation of the tumor ecosystem in reconstructed heterogeneous mouse mammary tumors. Cancer Res, 49, 3747-53.

    PubMed  CAS  Google Scholar 

  19. Miller BE, Miller FR, Machemer T and Heppner GH, 1993, Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumor. Br J Cancer, 68, 18-25.

    PubMed  CAS  Google Scholar 

  20. Tsai SCJ, Gansbacher B, Tait L, Miller FR and Heppner GH, 1993, Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst, 85, 546-53.

    Article  PubMed  CAS  Google Scholar 

  21. Miller BE, Aslakson CJ and Miller FR, 1990, Efficient recovery of clonogenic stem cells from solid tumors and occult metastatic deposits. Invasion Metastasis, 10, 101-12.

    PubMed  CAS  Google Scholar 

  22. Aslakson CJ, McEachern D, Conaway D and Miller FR, 1991, Inhibition of lung colonization at two different steps in the metastatic sequence. Clin Exp Metastasis, 9, 139-50.

    Article  PubMed  CAS  Google Scholar 

  23. Aslakson CJ, Rak JW, Miller BE and Miller FR, 1992, Differential influence of organ site on three subpopulations of a single mouse mammary tumor at two distinct steps in metastasis. Int J Cancer, 47, 466-72.

    Article  Google Scholar 

  24. Laport GF, Zimmermann TM, Grinblatt DL, Bitran J and Williams SF, 1996, High dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a ten year experience. Breast Cancer Res Treat, 41, 276.

    Google Scholar 

  25. Dillman RO, Barth NM, Nayak SK, DeLeon C, O'Connor A and Morrelli L, 1996, High-dose chemotherapy with autologous stem cell rescue in breast cancer. Breast Cancer Res Treat, 37, 277-89.

    Article  PubMed  CAS  Google Scholar 

  26. Dillman RO, Barth NM, VanderMolen L, Nayak SK, O'Connor A, et al. 1996, High-dose chemotherapy and peripheral blood stem cell rescue in breast cancer. Breast Cancer Res Treat, 41, 278.

    Google Scholar 

  27. Somlo G, Doroshow JH, Synold T, Chow W, Hamasaki V, et al. 1996, High-dose adriamycin, cyclophosphamide, and paxlitaxel for patients with high-risk and responsive stage IV breast cancer. Breast Cancer Res Treat, 41, 276.

    Google Scholar 

  28. Fields KK, Perkins JB, Partyka JS and Effenbein GJ, 1996, High dose therapy and autologous stem cell rescue in the treatment of breast cancer: novel regimens. Breast Cancer Res Treat, 41, 277.

    Google Scholar 

  29. Vahdat LT, Balmaceda C, Papadopoulos KP, Garrett TJ, Velez-Barone G, et al. 1996, Tandem high dose chemotherapy with escalating paclitaxel, melphalan and cytoxan, thiotepa, and carboplatin with peripheral blood progenitor support in responding metastatic breast cancer. Breast Cancer Res Treat, 41, 277.

    Google Scholar 

  30. Gluck S, Cano P, Dorreen M, Germond C, Lopez P, et al. 1996, High-dose cyclophosphamide, mitoxantrone and paclitaxel for the treatment of metastatic breast cancer with stem cell support. Breast Cancer Res Treat, 41, 277.

    Google Scholar 

  31. Cagnoni PJ and Shpall EJ, 1996, Mobilization and selection of CD34-positive hematopoietic progenitors. Blood Rev, 10, 1-7.

    Article  PubMed  CAS  Google Scholar 

  32. Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ and Ross M, 1996, High-dose chemotherapy with auto-logous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Semin Oncol, 23(1), Suppl. 2, 60-7.

    PubMed  CAS  Google Scholar 

  33. Obadina M, Verma U, Hawkins M and Mazumder A, 1996, Immunomodulation following chemotherapy. Breast Cancer Res Treat, 38, 41-8.

    Article  PubMed  CAS  Google Scholar 

  34. Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, et al. 1994, Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol, 12, 249-57.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Cancer Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA

    Bonnie E. Miller, Laine Delmonico, Kerry Vistisen & Fred R. Miller

Authors
  1. Bonnie E. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laine Delmonico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kerry Vistisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fred R. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, B.E., Delmonico, L., Vistisen, K. et al. Use of tumor lines with selectable markers in assessing the effect on experimental metastases of combination chemotherapy with alkylating agents. Clin Exp Metastasis 16, 480–488 (1998). https://doi.org/10.1023/A:1006541710377

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006541710377

Search

Navigation